Gilead Sciences (NASDAQ: GILD) is a Foster City, California-based biopharmaceutical company with leadership in HIV (Biktarvy, Descovy), viral hepatitis (Sovaldi, Harvoni, Epclusa), and a growing oncology franchise (Trodelvy, Yescarta, Tecartus).
Company Info
Upcoming Milestones & Key Dates
Q2 2026 earnings
ESMO presentations
Clinical Development Pipeline
Recent News
Gilead Sciences' Trodelvy (TROP-2 ADC) combined with Merck's Keytruda (PD-1 inhibitor) received FDA approvals for first-line treatment of metastatic triple-negative breast cancer and HR+/HER2- breast cancer.
Leadership Team
Chairman & Chief Executive Officer
Chief Financial Officer
Chief Medical Officer
Careers & Job Openings